<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157075</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00221267</org_study_id>
    <nct_id>NCT04157075</nct_id>
  </id_info>
  <brief_title>Intra-operative Uterosacral Ligament Bupivacaine Injection During Minimally Invasive Hysterectomy</brief_title>
  <official_title>The Effect of Intra-operative Uterosacral Bupivacaine Injection on Post-operative Pain in Patients Undergoing Minimally Invasive Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is proof of concept, phase I randomized controlled trial studying a short acting
      non-opioid anesthetic, bupivacaine to improve post-operative pain in gynecologic surgery
      patients. Patients who are undergoing minimally invasive (laparoscopic or robotic)
      hysterectomy will be randomized to receive no uterosacral injection, normal saline
      uterosacral injection, or 0.25% bupivacaine uterosacral injection just prior to colpotomy
      (incision around the cervix and removal of uterus) during minimally invasive hysterectomy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients will be blinded to which arm they are in, surgeon will not as they will be performing injection however will not be assessing pain scores</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in post-operative opioid usage with the use of uterosacral ligament bupivacaine injection</measure>
    <time_frame>7 days post-op</time_frame>
    <description>Total morphine equivalents of opioids in the first 7 days after surgery will be assessed to look for a statistically significant difference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Visual analog scores (VAS) scores following uterosacral ligament bupivicaine injection</measure>
    <time_frame>7 days post-op</time_frame>
    <description>Patient will report VAS scores at 2, 6, 12, 24, 48, 72 hours and then daily until post-op day 7 on a scale of 1-10 with higher scores indicating higher pain severity. The investigators will be looking for a statistically significant difference between the treatment and placebo vs. sham group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first bowel movement following uterosacral ligament bupivicaine injection</measure>
    <time_frame>7 days post-op</time_frame>
    <description>Patients will record when they resume normal bowel function on a pill diary post-operatively</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>No injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline Injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivicaine Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Bupivicaine injection into uterosacral ligaments prior to colpotomy</description>
    <arm_group_label>Bupivicaine Injection</arm_group_label>
    <arm_group_label>No injection</arm_group_label>
    <arm_group_label>Normal Saline Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women over the age of 18 years old

          -  undergoing benign minimally invasive hysterectomy with minimally invasive GYN surgeon
             at Johns Hopkins Hospital

          -  Patients must be English speaking.

        Exclusion Criteria:

          -  Pregnancy

          -  allergy, contraindication, or intolerance to bupivacaine, opioids, Tylenol, or NSAID
             drugs

          -  pre-operative daily opioid consumption

          -  peri-operative transverse abdominis plane block

          -  recent history of drug or alcohol abuse (in last year)

          -  severe cardiovascular, hepatic or renal disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja S Frost, MD</last_name>
    <phone>4104581977</phone>
    <email>afrost6@jhmi.edu</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

